Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PROCEPT BioRobotics (PRCT) Common Equity (2020 - 2025)

PROCEPT BioRobotics (PRCT) has disclosed Common Equity for 6 consecutive years, with $365.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Common Equity fell 9.04% to $365.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $365.9 million, a 9.04% decrease, with the full-year FY2025 number at $365.9 million, down 9.04% from a year prior.
  • Common Equity was $365.9 million for Q4 2025 at PROCEPT BioRobotics, down from $380.3 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $402.2 million in Q4 2024 to a low of -$206.3 million in Q2 2021.
  • A 5-year average of $232.5 million and a median of $258.4 million in 2022 define the central range for Common Equity.
  • Peak YoY movement for Common Equity: surged 268.21% in 2021, then plummeted 34.82% in 2023.
  • PROCEPT BioRobotics' Common Equity stood at $267.1 million in 2021, then dropped by 26.22% to $197.1 million in 2022, then soared by 42.46% to $280.8 million in 2023, then skyrocketed by 43.27% to $402.2 million in 2024, then fell by 9.04% to $365.9 million in 2025.
  • Per Business Quant, the three most recent readings for PRCT's Common Equity are $365.9 million (Q4 2025), $380.3 million (Q3 2025), and $385.8 million (Q2 2025).